| Patient | Ada Lovelace |
|---|---|
| Date of birth | 1990-12-10 |
| Identifiers | MRN HR-NI031-SYN; SSN (made up) 000-31-6729 |
| Document date | 2026-11-01 |
| Author | Constance Whitley-Adeyemi, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit for abnormal bleeding and pelvic pain: history, speculum examination and cervical biopsy, blood count and iron studies, conversion of opium tincture to measured oral morphine, an iron infusion, and a gynecologic oncology referral. Concerns: She wants to know plainly what the bleeding means and to make her own decisions; She wants her mornings clear-headed for her mathematical work and fears that stronger pain medicine will cloud her mind. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Opium tincture (100 mg/mL opium, equivalent to 10 mg/mL morphine), 0.5 mL by mouth four to six times a day as needed for pain | 0.5 mL four to six times a day as needed | Oral route | 2024-06-03 to 2026-06-02 | completed | S |
| Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain | 5 mg every 4 hours as needed | Oral route | 2026-06-02 | active | S |
| Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow whole | every 12 hours | Oral route | 2026-06-16 to 2026-10-20 | completed | S |
| Morphine sulfate extended-release 15 mg tablet, one tablet by mouth at night, for two weeks, then stop | once at night for two weeks, then stop | Oral route | 2026-10-20 | active | S |
| Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911 | one spray as needed for suspected overdose; repeat after 2 to 3 minutes if needed | Nasal route | 2026-06-02 | active | S |
| Senna 8.6 mg tablet, two tablets by mouth at night | two tablets at night | Oral route | 2026-06-02 | active | S |
| Polyethylene glycol 3350, 17 g in water by mouth once or twice a day | once daily, up to twice daily | Oral route | 2026-06-02 | active | S |
| Acetaminophen 500 mg tablet, two tablets by mouth three times a day | 1 g three times a day | Oral route | 2026-06-02 | active | S |
| Ferric carboxymaltose 750 mg intravenous infusion, two doses at the first two visits | 750 mg on two occasions two weeks apart | Intravenous route | 2026-06-02 to 2026-06-17 | completed | S |
| Pembrolizumab 200 mg intravenously every 3 weeks | every 3 weeks | Intravenous route | 2026-06-30 | active | S |
| Carboplatin, dose to an AUC of 5 (650 mg), intravenously every 3 weeks for six cycles | every 3 weeks for six cycles | Intravenous route | 2026-06-30 to 2026-10-13 | completed | S |
| Paclitaxel 175 mg/m2 (275 mg) intravenously every 3 weeks for six cycles, with premedication | every 3 weeks for six cycles | Intravenous route | 2026-06-30 to 2026-10-13 | completed | S |
| Ondansetron 8 mg tablet, one tablet by mouth twice a day for three days after each chemotherapy cycle, then as needed | twice a day for three days after each cycle, then as needed | Oral route | 2026-06-30 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Speculum examination with punch biopsy of an exophytic friable cervical mass, with a specimen for high-risk HPV typing; hemostasis with ferric subsulfate | 2026-06-02 to 2026-06-02 | completed | S |
| MRI of the pelvis: 5.2 cm endocervical tumor with left parametrial invasion, not reaching the pelvic sidewall; no hydronephrosis; enlarged left external iliac lymph node | 2026-06-09 to 2026-06-09 | completed | S |
| FDG PET-CT: avid cervical tumor; avid left pelvic and para-aortic lymph nodes; six avid nodules in both lungs up to 1.4 cm; no bone or liver lesions | 2026-06-11 to 2026-06-11 | completed | S |
| CT-guided core biopsy of a right lower lobe lung nodule: metastatic adenocarcinoma, p16 strongly positive and HPV 18 detected, matching the cervical primary; small apical pneumothorax not needing treatment | 2026-06-19 to 2026-06-19 | completed | S |
| Palliative external beam radiation to the pelvis for bleeding and pain, 20 Gy in 5 fractions over five days | 2026-06-22 to 2026-06-26 | completed | S |
| CT of chest, abdomen and pelvis after four cycles: partial response by RECIST 1.1, with the cervical tumor 3.1 cm, lung nodules smaller (largest 0.6 cm) and two resolved, para-aortic nodes below 1 cm; no new lesions | 2026-08-31 to 2026-08-31 | completed | S |
| Advance care planning conversation, about 30 minutes | 2026-08-18 to 2026-08-18 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-08-18 | Pneumococcal conjugate vaccine (PCV20) | completed | S |
| 2026-08-18 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
| 2026-08-18 | Tdap vaccine | completed | S |
| 2026-08-18 | Hepatitis B vaccine, CpG-adjuvanted (two-dose series), dose 1 of 2 | completed | S |
| 2026-10-20 | Influenza vaccine, inactivated, trivalent | completed | S |
| 2026-10-20 | COVID-19 mRNA vaccine, current season | completed | S |
| 2026-10-20 | Recombinant zoster vaccine, dose 2 of 2 | completed | S |
| 2026-10-20 | Hepatitis B vaccine, CpG-adjuvanted (two-dose series), dose 2 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1829 | Measles at 13, with a long recovery and about a year in bed | D (CLM-0002) |
| 1837 | Cholera at 21, followed by lingering asthma and digestive problems | D (CLM-0004) |
| from about 1843 | Chronic ill health from her late twenties, with episodes she called heart or rheumatic attacks, treated with several medicines including laudanum and opium | D (CLM-0005, CLM-0007) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | A poet; died at 36; cause not recorded in the cited source | D (CLM-0001) |
| Concern | Status | Evidence |
|---|---|---|
| She wants to know plainly what the bleeding means and to make her own decisions | active | S |
| She wants her mornings clear-headed for her mathematical work and fears that stronger pain medicine will cloud her mind | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 10.9 on 2026-10-20; MCV [Entitic mean volume] in Red Blood Cells by Automated count 74 on 2026-06-02; Leukocytes [#/volume] in Blood by Automated count 4.2 on 2026-10-20; Platelets [#/volume] in Blood by Automated count 188 on 2026-10-20; Ferritin [Mass/volume] in Serum or Plasma 210 on 2026-09-08; Creatinine [Mass/volume] in Serum or Plasma 0.71 on 2026-10-20; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 2026-10-20; Albumin [Mass/volume] in Serum or Plasma 3.6 on 2026-06-02; Choriogonadotropin.beta subunit [Units/volume] in Serum or Plasma 1 on 2026-06-02; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 114 on 2026-10-20; Pain severity - 0-10 verbal numeric rating [Score] - Reported 2 on 2026-10-20; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 on 2026-10-20; Thyrotropin [Units/volume] in Serum or Plasma 7.8 on 2026-10-20; Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1 on 2026-10-20; Potassium [Moles/volume] in Serum or Plasma 3.8 on 2026-07-07; Calcium [Mass/volume] in Serum or Plasma 9.3 on 2026-07-07; Neutrophils [#/volume] in Blood by Automated count 2.4 on 2026-10-20; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 2 on 2026-08-18 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bleeding between periods and after intercourse, with heavier periods, a watery blood-stained discharge and a constant pelvic ache, for about five months; average pain 7 of 10 despite her opium tincture; a friable cervical mass found on examination and biopsied; cause not yet established at intake | resolved | confirmed | N93.8 | S — Synthetic presenting problem anchored to her documented final illness; superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic blood loss: hemoglobin 8.4 g/dL, mean cell volume 74 fL, ferritin 5 ng/mL, with tiredness and breathlessness on stairs | active | confirmed | D50.0 | S — Synthetic modern finding anchored to her documented final illness. |
| Adenocarcinoma of the endocervix, usual (HPV-associated) type, HPV 18 positive, FIGO 2018 stage IVB: a 5.2 cm tumor with left parametrial invasion, metastases to left pelvic and para-aortic lymph nodes, and bilateral lung metastases on MRI and PET-CT; PD-L1 combined positive score 5, mismatch repair proficient, HER2 1+; treated with palliative pelvic radiation for bleeding and carboplatin, paclitaxel and pembrolizumab, with specialist palliative care from diagnosis | active | confirmed | C53.0 | S — Synthetic modern diagnosis made at the second visit, anchored to her documented uterine cancer; the cervical site is a synthetic choice. |
| Cancer-related pelvic pain, nociceptive and visceral, from the cervical tumor and its left parametrial extension | active | confirmed | G89.3 | S — Synthetic modern diagnosis made at the second visit. |
| Long-term prescribed opioid therapy: opium tincture for recurrent pelvic and abdominal pain for about two years, measured at times with a household spoon, converted at intake to measured oral morphine; no opioid use disorder on a DSM-5 assessment; naloxone supplied | active | confirmed | Z79.891 | S — Synthetic modern history anchored to her documented laudanum and opium; not a claim about her real dosing. |
| Drug-induced constipation from long-acting morphine and ondansetron, a week after the first chemotherapy cycle: no bowel movement for five days, with bloating and cramping but passing wind, without vomiting; no bowel obstruction on examination; potassium and calcium normal; resolved with laxatives | resolved | confirmed | K59.03 | S — Synthetic adverse drug effect; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-02 | Hemoglobin [Mass/volume] in Blood | 8.4 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-06-02 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 74 | fL | 80-100 fL | Low | S |
| 2026-06-02 | Leukocytes [#/volume] in Blood by Automated count | 7.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-06-02 | Platelets [#/volume] in Blood by Automated count | 412 | 10*3/uL | 150-400 10*3/uL | High | S |
| 2026-06-02 | Ferritin [Mass/volume] in Serum or Plasma | 5 | ng/mL | 15-150 ng/mL | Low | S |
| 2026-06-02 | Creatinine [Mass/volume] in Serum or Plasma | 0.68 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 2026-06-02 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | 7-35 U/L | Normal | S |
| 2026-06-02 | Albumin [Mass/volume] in Serum or Plasma | 3.6 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-06-02 | Choriogonadotropin.beta subunit [Units/volume] in Serum or Plasma | 1 | m[IU]/mL | Below 5 is negative | Normal | S |
| 2026-06-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 116 | mL/min/{1.73_m2} | 60 or more | Normal | S |
| 2026-06-02 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 7 | {score} | S | ||
| 2026-06-02 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-06-16 | Hemoglobin [Mass/volume] in Blood | 9 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-06-16 | Creatinine [Mass/volume] in Serum or Plasma | 0.66 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 2026-06-16 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 17 | U/L | 7-35 U/L | Normal | S |
| 2026-06-16 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-06-16 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-06-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 117 | mL/min/{1.73_m2} | 60 or more | Normal | S |
| 2026-06-16 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 6 | {score} | S | ||
| 2026-07-07 | Potassium [Moles/volume] in Serum or Plasma | 3.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-07 | Calcium [Mass/volume] in Serum or Plasma | 9.3 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-07-14 | Hemoglobin [Mass/volume] in Blood | 9.8 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-07-14 | Leukocytes [#/volume] in Blood by Automated count | 4.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-07-14 | Neutrophils [#/volume] in Blood by Automated count | 2.2 | 10*3/uL | 1.8-7.7 10*3/uL | Normal | S |
| 2026-07-14 | Platelets [#/volume] in Blood by Automated count | 236 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-07-14 | Creatinine [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 2026-07-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-35 U/L | Normal | S |
| 2026-07-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 116 | mL/min/{1.73_m2} | 60 or more | Normal | S |
| 2026-07-14 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 3 | {score} | S | ||
| 2026-07-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | {score} | S | ||
| 2026-09-08 | Hemoglobin [Mass/volume] in Blood | 10.6 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-09-08 | Leukocytes [#/volume] in Blood by Automated count | 3.8 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 2026-09-08 | Neutrophils [#/volume] in Blood by Automated count | 1.9 | 10*3/uL | 1.8-7.7 10*3/uL | Normal | S |
| 2026-09-08 | Platelets [#/volume] in Blood by Automated count | 172 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-09-08 | Creatinine [Mass/volume] in Serum or Plasma | 0.72 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 2026-09-08 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-35 U/L | Normal | S |
| 2026-09-08 | Thyrotropin [Units/volume] in Serum or Plasma | 3.4 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-09-08 | Ferritin [Mass/volume] in Serum or Plasma | 210 | ng/mL | 15-150 ng/mL | High | S |
| 2026-09-08 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 112 | mL/min/{1.73_m2} | 60 or more | Normal | S |
| 2026-09-08 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 3 | {score} | S | ||
| 2026-09-08 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-10-20 | Hemoglobin [Mass/volume] in Blood | 10.9 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-10-20 | Leukocytes [#/volume] in Blood by Automated count | 4.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-10-20 | Neutrophils [#/volume] in Blood by Automated count | 2.4 | 10*3/uL | 1.8-7.7 10*3/uL | Normal | S |
| 2026-10-20 | Platelets [#/volume] in Blood by Automated count | 188 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-10-20 | Creatinine [Mass/volume] in Serum or Plasma | 0.71 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 2026-10-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-35 U/L | Normal | S |
| 2026-10-20 | Thyrotropin [Units/volume] in Serum or Plasma | 7.8 | m[IU]/L | 0.45-4.5 mIU/L | High | S |
| 2026-10-20 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-10-20 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 114 | mL/min/{1.73_m2} | 60 or more | Normal | S |
| 2026-10-20 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | {score} | S | ||
| 2026-10-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-08-18 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 2 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-02 | Body height | 165 | cm | S |
| 2026-06-02 | Body weight | 54 | kg | S |
| 2026-06-02 | Body mass index (BMI) [Ratio] | 19.8 | kg/m2 | S |
| 2026-06-02 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-06-02 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-06-02 | Heart rate | 96 | /min | S |
| 2026-06-02 | Respiratory rate | 16 | /min | S |
| 2026-06-02 | Body temperature | 36.8 | Cel | S |
| 2026-06-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-06-16 | Body height | 165 | cm | S |
| 2026-06-16 | Body weight | 54.2 | kg | S |
| 2026-06-16 | Body mass index (BMI) [Ratio] | 19.9 | kg/m2 | S |
| 2026-06-16 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-06-16 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-06-16 | Heart rate | 92 | /min | S |
| 2026-06-16 | Respiratory rate | 16 | /min | S |
| 2026-06-16 | Body temperature | 36.7 | Cel | S |
| 2026-06-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-07-14 | Body height | 165 | cm | S |
| 2026-07-14 | Body weight | 53.4 | kg | S |
| 2026-07-14 | Body mass index (BMI) [Ratio] | 19.6 | kg/m2 | S |
| 2026-07-14 | Systolic blood pressure | 110 | mm[Hg] | S |
| 2026-07-14 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-07-14 | Heart rate | 84 | /min | S |
| 2026-07-14 | Respiratory rate | 16 | /min | S |
| 2026-07-14 | Body temperature | 36.6 | Cel | S |
| 2026-07-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-08 | Body height | 165 | cm | S |
| 2026-09-08 | Body weight | 54 | kg | S |
| 2026-09-08 | Body mass index (BMI) [Ratio] | 19.8 | kg/m2 | S |
| 2026-09-08 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-09-08 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-09-08 | Heart rate | 80 | /min | S |
| 2026-09-08 | Respiratory rate | 16 | /min | S |
| 2026-09-08 | Body temperature | 36.7 | Cel | S |
| 2026-09-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-20 | Body height | 165 | cm | S |
| 2026-10-20 | Body weight | 54.4 | kg | S |
| 2026-10-20 | Body mass index (BMI) [Ratio] | 20 | kg/m2 | S |
| 2026-10-20 | Systolic blood pressure | 114 | mm[Hg] | S |
| 2026-10-20 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-10-20 | Heart rate | 78 | /min | S |
| 2026-10-20 | Respiratory rate | 16 | /min | S |
| 2026-10-20 | Body temperature | 36.6 | Cel | S |
| 2026-10-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-08-18 | Body height | 165 | cm | S |
| 2026-08-18 | Body weight | 53.6 | kg | S |
| 2026-08-18 | Body mass index (BMI) [Ratio] | 19.7 | kg/m2 | S |
| 2026-08-18 | Systolic blood pressure | 110 | mm[Hg] | S |
| 2026-08-18 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-08-18 | Heart rate | 80 | /min | S |
| 2026-08-18 | Respiratory rate | 16 | /min | S |
| 2026-08-18 | Body temperature | 36.6 | Cel | S |
| 2026-08-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-07-07 | Body height | 165 | cm | S |
| 2026-07-07 | Body weight | 53.8 | kg | S |
| 2026-07-07 | Body mass index (BMI) [Ratio] | 19.8 | kg/m2 | S |
| 2026-07-07 | Systolic blood pressure | 110 | mm[Hg] | S |
| 2026-07-07 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-07-07 | Heart rate | 88 | /min | S |
| 2026-07-07 | Respiratory rate | 16 | /min | S |
| 2026-07-07 | Body temperature | 36.7 | Cel | S |
| 2026-07-07 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-06-02 | New patient visit for abnormal bleeding and pelvic pain: history, speculum examination and cervical biopsy, blood count and iron studies, conversion of opium tincture to measured oral morphine, an iron infusion, and a gynecologic oncology referral | finished | S |
| 2026-06-16 | Two-week follow-up and gynecologic oncology consultation: pathology, MRI and PET-CT, staging, treatment intent, palliative care, and long-acting morphine | finished | S |
| 2026-07-14 | Six-week review: bleeding and pain after palliative pelvic radiation, the first cycle of chemotherapy with pembrolizumab, blood counts, mood and opioid safety | finished | S |
| 2026-09-08 | Fourteen-week review: restaging CT, blood counts, iron and thyroid, pain, and a goals-of-care conversation | finished | S |
| 2026-10-20 | Twenty-week review after the last chemotherapy cycle: blood counts, thyroid on pembrolizumab, tapering morphine, mood and her work | finished | S |
| 2026-08-18 | Periodic adult preventive visit | finished | S |
| 2026-07-07 | Same-day sick visit for constipation | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Gynecologic oncology consultation in two weeks for a friable cervical mass with bleeding and pain, biopsied today: diagnosis, staging, treatment intent, bleeding control, and pain | completed | GL-NCCN-CERV-2026, GL-FIGO-2018 | S |
| Stop opium tincture and change to measured oral morphine solution 5 mg every 4 hours as needed with an oral syringe, with acetaminophen, senna and polyethylene glycol, a naloxone nasal spray, a prescription monitoring check, locked storage, one prescriber, and review in two weeks | completed | GL-ASCO-OPIOID-2023, GL-CDC-OPIOID-2022 | S |
| Iron deficiency anemia: ferric carboxymaltose 750 mg intravenously today and in two weeks, with a blood count at each visit and ferritin 6 to 8 weeks after the infusions | completed | GL-CMID-2026 | S |
| Blood tests: blood count, ferritin, creatinine, ALT, albumin and a pregnancy test; HIV, hepatitis B and hepatitis C tests before any cancer treatment; PHQ-9 | completed | GL-ASCO-HBV-2020, GL-USPSTF-DEP-2023 | S |
| Staging by FIGO 2018 with pelvic MRI and PET-CT, and a CT-guided biopsy of a lung nodule; tumor PD-L1, mismatch repair and HER2 testing; no germline testing, because cervical cancer is not a hereditary cancer syndrome | completed | GL-NCCN-CERV-2026, GL-FIGO-2018 | S |
| Palliative pelvic radiation, 20 Gy in 5 fractions, for bleeding and pain, then carboplatin, paclitaxel and pembrolizumab every 3 weeks for six cycles with pembrolizumab continuing, without bevacizumab while bleeding and after pelvic radiation; blood counts before each cycle and thyroid tests every six weeks | completed | GL-NCCN-CERV-2026, GL-KN826-2021 | S |
| Specialist palliative care alongside cancer treatment from diagnosis, for pain, symptoms, mood, and goals-of-care conversations, with long-acting morphine 15 mg every 12 hours and oral morphine 5 mg as needed for breakthrough pain | completed | GL-ASCO-PALL-2024, GL-ASCO-OPIOID-2023, GL-ASCO-COMM-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Average pelvic pain at or below 3 of 10 without daytime sedation | 2026-07-14 | completed | Average pain 3 of 10 after radiation, on long-acting morphine, without daytime sleepiness | S |
| Bleeding controlled and hemoglobin above 10 g/dL without transfusion | 2026-09-08 | completed | No bleeding since radiation; hemoglobin 10.6 g/dL | S |
| A documented goals-of-care conversation and a named health care agent | 2026-09-08 | completed | Advance care plan and goals-of-care conversation recorded | S |
| Able to work on her mathematics for at least two hours most mornings | 2026-10-20 | completed | Working most mornings | S |